PhageNova Bio, Inc.
Biotechnology company developing ligand-directed, systemically administered gene delivery vectors based on an engineered bacteriophage/adeno-associated virus hybrid. The organization is advancing preclinical and IND-enabling studies, GMP manufacturing, and first-in-human clinical planning for oncology applications while also applying the platform to vaccine development and pulmonary delivery.
Industries
N/A
Products
PNB-001 (lead oncology development candidate)
Lead ligand-directed hybrid bacteriophage–AAV vector program targeting solid tumors; undergoing IND-enabling studies, toxicology, and GMP manufacturing preparatory to a Phase 1 clinical trial.
PNB-V01 (phage-based vaccine platform)
Platform for phage-based vaccines designed to display viral epitopes on capsid surfaces and to deliver antigen transgenes to lymphoid and pulmonary tissues, including aerosol formulations intended to be cold-chain independent.
PNB-001 (lead oncology development candidate)
Lead ligand-directed hybrid bacteriophage–AAV vector program targeting solid tumors; undergoing IND-enabling studies, toxicology, and GMP manufacturing preparatory to a Phase 1 clinical trial.
PNB-V01 (phage-based vaccine platform)
Platform for phage-based vaccines designed to display viral epitopes on capsid surfaces and to deliver antigen transgenes to lymphoid and pulmonary tissues, including aerosol formulations intended to be cold-chain independent.
Expertise Areas
- Targeted gene delivery
- Ligand discovery and targeting
- Preclinical development and toxicology
- GMP manufacturing and CMC
Key Technologies
- Hybrid bacteriophage–AAV vectors
- Ligand-directed targeting
- Transgene payload engineering
- Pulmonary/aerosol delivery formulations